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ABSTRACT: With the aim of combining the potential anticancer properties of both clotrimazole, an imidazole based antifun-
gal agent, and silver(I)-N-heterocyclic carbenes, thirteen novel silver(I)-N-heterocyclic carbene complexes derived from clot-
rimazole were synthesized. The complexes were fully characterized and the partition coefficient of each was determined to 
provide a measure of hydrophobicity. The antiproliferative properties of the complexes against cancerous and non-cancerous 
cell lines found optimum cytotoxicity when the complex displays an “intermediate lipophilicity”, which describes a complex 
that possesses both water-soluble groups and lipophilic aromatic groups. The silver complexes were screened on a synthetic 
biomembrane-like device using a chip-based phospholipid coated Pt/Hg electrode embedded in a flow cell system. The results 
are recorded as rapid cyclic voltammograms (RCVs), which give insight into the interactions of the complexes with a cell membrane. Interestingly the principle of “intermediated lipophilicity” also applies to the monolayer interaction to which the 
silver atom significantly implements an irreversibility. 
INTRODUCTION: The serendipitous discovery of cisplatin 
as an anticancer agent by Rosenberg at the end of the 1960s 
opened up a new area of research in organometallic chem-
istry for the treatment of cancer.1 Despite the success of cis-
platin and other platinum-based drugs, severe side-effects 
and the development of drug resistance are drawbacks to 
their clinical applications.2-3 Therefore, research efforts 
have also examined the potential of other metals as chemo-
therapeutic agents. Complexes of ruthenium,4-6 iron7 and ti-
tanium8 exhibit significant cytotoxic effects, with some ru-
thenium complexes having undergone clinical trials.9 Silver 
is another metal that has been studied for its biomedicinal 
properties as it is thought to have relatively low toxicity, 
with the antimicrobial properties of this metal having being 
exploited for centuries.10 In recent years, studies have 
shown that silver also has potential in the field of cancer 
chemotherapy.11-13 
Over the last few decades, N-heterocyclic carbenes (NHCs) 
have become ubiquitous ligands in organometallic chemis-
try, particularly in the field of catalysis.14-23  In recent years, 
metal-NHCs have shown promise in biomedical applica-
tions, including as antimicrobial (silver-NHCs) and as anti-
tumor (palladium-, copper-, silver-, gold-, ruthenium and 
platinum-NHCs) agents.12, 24-41 The efficacy of a silver-based 
drug appears to be linked to its bioavailability,29, 42 which is 
affected by, for example, solubility and the presence of bio-
logical ligands and halides. The release rate of silver from a 
pro-drug is linked to the ancillary ligand and, as NHCs are 
strong σ-donors, silver-NHCs can have a slow silver release 
rate. It is imperative that the ligand also has a low toxicity 
profile.  
Clotrimazole (Figure 1A) is an imidazole-containing com-
pound, and is a highly effective treatment for fungal dis-
eases in plants, humans and animals.43 It is a readily availa-
ble material that is already present in many pharmaceutical 
treatments, administered both orally and topically for infec-
tions such as dermatophytes and staphylococci. Once ad-
ministered, clotrimazole can be metabolized and excreted 
from the body (Figure 1B and C).44 Clotrimazole also shows 
activity against various tumor cell lines, and is thought to be 
effective by decreasing the movement of intracellular Ca2+ 
and K+ ions.45 Its ability to interact with cell membranes and 
penetrate cells can be attributed to its aromaticity.46 As clot-
rimazole is an imidazole-containing compound, possessing 
negligible toxicity and anticancer properties, it is an ideal 
precursor to silver-NHCs for examination as chemothera-
peutic agents. Herein we report the synthesis, characteriza-
tion and bioactivity of a family of silver(I)-NHCs prepared 
from clotrimazole-derived imidazolium salts. The com-
plexes were screened against cancerous cell lines including 
 
Figure 1. Active antifungal compound clotrimazole (A), and its 





Scheme 1. Synthesis of imidazolium salts 1a, 1c and 1e starting from clotrimazole (A & B), 2a-e starting from 2-chlorotrityl 
chloride (C) and 3a-e from trityl chloride (D), and silver-NHC complexes. Box: Solution equilibria between 2Ag(NHC)X and 
[Ag(NHC)2]AgX2 with removal of AgX to form [Ag(NHC)2]X. 
the pancreatic cancer cell lines, Panc 10.05 and MIA PaC-
2, and the colorectal carcinoma BE cell line plus the non-
cancerous cell line APRE-19 in order to assess both their 
cytotoxicity and selectivity. As clotrimazole inhibits prolif-
erating cells by affecting the transport of ions across the 
plasma membrane,45 the silver complexes and corre-
sponding ligand precursors have been screened on a bio-
sensing device which measures their interaction with a 
phospholipid sensor element, to provide an indication of 
their biological membrane activity.47 
RESULTS AND DISCUSSION: Imidazolium salts 1a and 1c 
were prepared using microwave conditions (Scheme 1A) 
and fully characterized.  Crystals suitable for X-ray crystal-
lography were grown via diffusion of diethyl ether into a 
solution of either 1a or 1c in dichloromethane (See SI). 
The solid-state structures show the expected imidazolium 
iodide salts, with no evidence of hydrogen bonding or an-
ion-π interactions between the iodide anion and the imid-
azolium ring.48 Such interactions are likely to be precluded 
by the presence of the bulky trityl group adjacent to the 
imidazolium ring. Interestingly, an anion-π interaction 
does appear to exist between the aryl-chloride and the im-
idazolium ring in 1c, with an aryl-Cl···imidazolium cen-
troid distance of 3.28 Å. In contrast to 1a and 1c, we found 
that imidazolium salt 1e could instead be prepared more 
efficiently through reaction of the reagents in dichloro-
methane at reflux (Scheme 1B). Crystals suitable for X-ray 
crystallography were grown via diffusion of diethyl ether 
into a solution of 1e in dichloromethane. The structure 
shows the expected imidazolium salt, however, the anion 
(labelled I(1)) is substitutionally disordered, containing a 
mixture of chloride (29 %) and iodide (71 %) (See SI). The 
chloride may originate from impurities in the dichloro-
methane solvent, however, it is likely that this observation 
is a result of exchange between the iodide anion and the 
chloride of the 2-chlorotrityl group. This is further evi-
denced through the aryl-halide group (labelled Cl(1)) also 
being present as a mixture of chloride (97 %) and iodide 
(3 %). To prevent the formation of imidazolium salts with 
disordered halides, N-substituted imidazoles were re-
acted with 2-chlorotrityl chloride in acetonitrile or di-
chloromethane at reflux, to yield imidazolium compounds 
2a-e (Scheme 1C). With the interest of investigating the 
effect of the 2-chlorotrityl group within the ligand on the 
anticancer activity of the silver complexes, a second set of 
imidazolium compounds 3a-e were synthesized in the 
same manner, starting with trityl chloride (Scheme 1D). 
The compounds were fully characterized, with crystals of 
2a, 2b, 2d, 2e and 3e suitable for X-ray diffraction analysis 
being grown by diffusion of either diethyl ether or pentane 
into either dichloromethane or methanol solutions of the 
compounds (See SI). 
Reaction of the imidazolium salts with Ag2O resulted in 
formation of complexes of the type Ag(NHC)X (where X = 
halide), [Ag(NHC)2]X (where X = halide and/or AgX2-) or a 
combination of the two. Solution equilibria between 
2Ag(NHC)X and [Ag(NHC)2]AgX2 is a common phenome-
non observed in silver-NHCs and is not observed on the 
NMR timescale here (Scheme 1).13, 29, 49-51 Equilibration of 
these species is known to occur on very different time-
scales in different media.52 As the complexes were filtered 
through Celite during work-up, some AgX was removed 
from the bis-NHCs, resulting in X rather than AgX2 coun-
terions in the cationic species (X = Cl, I). Silver-NHC 
 
 
             
 
 
           
Figure 2. Molecular structures of silver-NHC complexes 4e, 5a, 5b, 5d and 6c. Hydrogen atoms and water molecules have been 
omitted for clarity. Ellipsoids are shown at 50 % probability for 5a and 5b, 40 % for 5d and 35 % for 4e and 6c.
Figure 3. Bar chart to show the log P values for complexes 
4-6. 
complexes were fully characterized using NMR spectros-
copy, high-resolution mass spectrometry and elemental 
analysis, which revealed the ratios of X- to AgX2- counter-
anions, and solid-state structures were obtained for com-
plexes 4e, 5a, 5b, 5d and 6c (Figure 2). The molecular 
structures reveal that the mono- and bis-NHC complexes 
have similar bond distances between the silver and the 
carbenic carbon atoms (2.08-2.12 Å), and similar NCN 
bond angles between the carbenic carbon and neighbor-
ing nitrogen atoms (103-106 °). The geometry around the 
silver centers distort slightly from linearity, with Ccarbene-
Ag-Ccarbene/X bond angles ranging 171.2(7) ° for 6c, to 
176.42(14) ° for 5a. 
As a means to assess the affinity of complexes 4-6 for the 
phospholipid component of the cell membrane, the parti-
tion coefficient (log P) of the thirteen complexes and cis-
platin was measured. The results are summarized in Fig-
ure 3, with log P values ranging from 0.26 (±0.06) (5e) to 
more hydrophobic 0.59 (±0.07) (6c). Cisplatin, with a log 
P value of -1.35 (±0.26), is more hydrophilic than any of 
the silver-NHC complexes tested. Three trends relating to 
hydrophobicity can be observed from Figure 3; i) Com-
plexes 4a-e, with a Cl substituent on the triphenyl group 
appear more hydrophobic than the corresponding com-
plexes 5a-e, where the Cl is replaced with a H; ii) The ben-
zyl containing complexes 4d and 5d are the most  hydro-
phobic in their series followed by butyl, allyl, methyl and 
hydroxyethyl containing complexes; iii) Substituting  the 
chloride counterion  for an iodide anion in  complexes 6a, 




Figure 4. Bar chart to show IC50 values for complexes 4-6 in comparison to cisplatin against Panc 10.05, MIA PaCa-2 and BE 
cancerous cell lines and ARPE-19 non-cancerous cell line. 
Cell Line Panc 10.05 Mia-PaCa-2 BE ARPE-19 
Cisplatin 1.7 ± 0.4 (3.75) 2.8 ± 2.0 (2.26) 0.7 ± 0.3 (9.71) 6.4 ± 0.9 
4a 7.1 ± 3.7 (7.04*) 11.7 ± 1.6 (4.27*) 18.0 ± 4.4 (2.77*) >50 
4b 9.4 ± 5.6 (1.22) 6.3 ± 4.8 (1.82) 6.7 ± 1.1 (1.71) 11.5 ± 2.9 
4c 13.5 ± 2.8 (1.42) - - 19.2 ± 3.7 
4d 5.8 ± 1.4 (1.78) 7.0 ± 1.6 (1.46) 8.4 ± 1.2 (1.21) 10.2 ± 0.8 
4e 1.9 ± 0.7 (17.47) 4.9 ± 1.8(6.62) 8.5 ± 6.8 (3.80) 32.5 ± 6.6 
5a 16.1 ± 0.9 (1.66) - - 26.6 ± 7.8 
5b 16.1 ± 1.9 (1.71) - - 27.5 ± 7.5 
5c 16.8 ± 1.8 (0.82) - - 13.8 ± 6.5 
5d 13.8 ± 1.8 (3.35) - - 46.3 ± 4.7 
5e 6.5 ± 4.5 (6.30) 8.6 ± 1.9 (4.78) 9.0 ± 4.3 (4.56) 41.2 ± 6.2 
6a 10.0 ± 6.8 (2.41) 5.7 ± 2.3 (4.23) 3.3 ± 1.2 (7.31) 24.2 ± 2.6 
6c 3.8 ± 1.9 (2.25) 4.5 ± 3.9 (1.91) 3.6 ± 0.9 (2.42) 8.7 ±1.5 
6e 20.5 ± 12.6 (1.27) 10.6 ± 3.2 (2.28) 3.1 ± 0.5 (8.51) 26.0 ± 1.7 
Table 1. Responses of Panc 10.05, Mia-PaCa-2 and BE cancerous cell lines and ARPE-19 non-cancerous cell line to silver-NHC 
complexes 4-6. Values presented are IC50 (µM) ±SD for three independent experiments. The values in parenthesis represent 
the selectivity ratio defined as the IC50 value for ARPE-19 cells divided by the IC50 for each of the cancer cell lines tested. * 
Minimum possible value as the value for ARPE-19 is 50 µM (highest concentration tested). 
6c and 6e increases the hydrophobicity of the complexes 
when compared to their analogous chloride complexes 4a, 
4c and 4e. The higher lipophilicity of complexes 6a, 6c and 
6e was anticipated as a larger iodide anion with a higher 
molar mass provides greater polarizability than a chloride 
anion. The in vitro cytotoxicity of silver-NHC complexes 4-
6 was determined using MTT-based assays following a 96-
hour drug-exposure period. Compounds were initially 
tested for their activity against pancreatic adenocarci-
noma cell line Panc 10.05 and the non-cancer ARPE-19 cell 
line. Compounds with higher selectivity index (defined as 
the ratio of mean IC50 values for ARPE-19 cells divided by 
the mean IC50 in cancer cells) than cisplatin (4a, 4e and 
5e) were evaluated further by assessing their antiprolifer-
ative activity against pancreatic carcinoma MIA PaC-2 and 
colorectal carcinoma BE. Complexes 4b, 4d, 6a, 6c and 6e 
were also tested against all 4 cell lines to determine 
whether low selectivity ratios were also observed in other 
cell lines and the results are summarized in Figure 4 and 
Table 1. From the MTT assays it can be seen that the 2-
chlorotrityl-bearing silver-NHC complexes 4a-4e are gen-
erally more cytotoxic against Panc 10.05 than their corre-
sponding trityl-bearing complexes 5a-5e, indicating that 
the presence of an aryl-Cl group plays a role in the activity 
of these complexes. This could be due to the fact that the 
Cl group increases the propensity of the complexes to in-
teract with phospholipid and cell membranes.53 Complex 
4e is the most active against Panc 10.05 of all thirteen 
complexes tested, and exhibits an IC50 value that is compa-
rable to cisplatin (p>0.05). The hydroxyethyl group in-
creases the hydrophilicity of the complex (lower log P), 
thus enhancing the water solubility which also improves 
cytotoxicity. Changing the counterion from chloride on 
complex 4c to iodide in complex 6c improves the cytotox-
icity against Panc 10.05 (p<0.01). However, when iodide 
complex 6e was tested against Panc 10.05 it revealed nu-
merical inferior activity compared to its corresponding 
chloride containing analogues 4e (although the difference 
 
did not reach statistical significance p>0.05), with com-
plexes 4a (chloride) and 6a (iodide) exhibiting similar ac-
tivity to each other (p>0.05). In general, iodide-containing 
complexes such as 6c displays comparable cytotoxicity 
against all cell lines tested compared to their chloride an-
alogues 4a (p>0.05) and 4c (p>0.05) when the N-substit-
uent is methyl or nbutyl. The reverse is observed when the 
N-substituent is hydroxyethyl, with chloride-containing 
complex 4e displaying greater cytotoxicity when com-
pared to its iodide analogue 6e against Panc 10.0 cells 
(p<0.05). This difference was however cell line depend-
ent, with 6e showing greater activity against BE cells than 
4e (although this didn’t reach statistical significance, 
p>0.05). These differences in trend indicate that there is a 
fine balance between groups within the overall complex, 
with modification of one moiety influencing the effect of 
another. 
All the silver complexes were evaluated against the non-
cancerous retinal epithelial cell line ARPE-19 to evaluate 
their selectivity towards cancerous cells (Table 1). Com-
plexes 4a, 4e and 5e show greatest selectivity towards the 
cancerous Panc 10.05 over the non-cancerous ARPE-19, 
with selectivity ratios higher than cisplatin. Complex 4e, 
the most active of the thirteen complexes, is also the most 
selective towards Panc 10.05, exhibiting a selectivity ratio 
of 17.47, which is almost 5-fold the selectivity of cisplatin. 
Complex 4e also exhibits the highest selectivity ratio for 
cancerous MIA PaCa-2 over non-cancerous ARPE-19, 
while 6e displays the highest selectivity for cancerous BE 
over ARPE-19. Across the panel of cell lines, selectivity in-
dices were comparable for compounds 4b, 4d and 6c (Ta-
ble 1). For compounds 4e, 6a and 6e however, selectivity 
ratios were cell line dependent reflecting inherent differ-
ences in cancer cell sensitivity to these compounds (Table 
1).  Whilst the increase in SI values for 6a (7.31) and 6e 
(8.51) against BE cells were less than the SI for cisplatin 
(9.71), these results suggest that caution should be exer-
cised with regards to selecting compounds based on SI val-
ues obtained for one cell line.  
Clotrimazole has been evaluated against MCF7 and MDA-
MB-231 breast cancer cells lines and its activity compared 
with the response of non-tumourigenic MCF10A cells.54 
Whilst clotrimazole completely and preferentially inhib-
ited the proliferation of MCF10A cells, there was selective 
cell kill (as determined by trypan blue exclusion, LDH re-
lease and the MTT assay) in MCF7 and MDA-MB-231 cells. 
As the cells were immediately analyzed following drug ex-
posure (24 hour duration), the results are not directly 
comparable to the results of this study but do indicate that 
clotrimazole itself has some inherent selectivity for cancer 
cells in vitro. 
To help assess the potential impact of silver complexes on 
the biomembrane, a membrane-based sensing device was 
utilized to test the putative biomembrane activity of the 
thirteen complexes 4-6 and cisplatin.47, 55-60 This device 
consists of an electrode-supported monolayer of dioleoyl 
phosphatidylcholine (DOPC) which has been validated 
against DOPC bilayer vesicles showing identical interac-
tions with biomembrane-active compounds. The DOPC 
monolayer is deposited on a microfabricated Pt/Hg elec-
trode which is connected to an on-line high-throughput 
flow system and utilizes rapid cyclic voltammetry (RCV) 
to display changes in capacitance current peaks when a 
voltage scan of 40 V s-1 is applied.56 The DOPC monolayer 
undergoes two potential-induced phase transitions repre-
sented by two characteristic sharp capacitance current 
peaks from -0.4 to -1.2V (vs Ag/AgCl). The two  sequential  
reversible  transitions correspond to the entrance of elec-
trolyte into the layer coincident with pore formation and 
the re-organization of the layer to form a patchy bilayer, 
respectively.58 The interaction of the complexes with the 
layer can be observed by changes in the current peak con-
figurations representative of phospholipid monolayer 
damage as well as increases in the baseline capacitance 
current informing on how well the complexes and/or wa-
ter penetrate monolayer sensor element.60 
Initially, screening of silver complexes 4e, 5d, 5e, 6a, 6c 
and 6d prepared at 50 µM solutions displayed differences 
in interactions with DOPC (Figure 5, left), which could be 
related to variations in ligand N-substituents and pres-
ence/absence of Cl on the triphenyl group. Comparison of 
interactions of the hydroxyethyl containing complexes 4e, 
5e and 6e with DOPC indicates that the chloride on the tri-
phenyl group increases the interaction with the DOPC sen-
sor element, as 5e shows less interaction than the chloride 
containing 4e and 6e. The effect of chloride as an aromatic 
substituent in promoting interaction with the lipid has 
been shown previously.53, 61 Changing the N-substituent 
from a hydroxyethyl in 6e to a methyl in 6a or an nbutyl in 
6c decreases the interaction with the sensor element, 
which indicates that improving the water solubility 
through addition of a hydroxyethyl substituent may im-
prove the kinetics of interaction at the monolayer surface. 
Conversely, changing the N-substituent to a benzyl ap-
pears to increase the interaction with the DOPC, even 
more than hydroxyethyl, which is shown by the difference 
between the interactions shown by the RCVs of 5d and 5e. 
This is not unusual as aromatic rings are reported to pro-
mote phospholipid monolayer interaction.53, 61 The de-
creased interaction of 6e compared to 4e with the DOPC 
layer can be attributed to the larger iodide atom on 6e 
which, although it increases the hydrophobicity of the 
complex, has some steric or related effect which inhibits 
compound penetration of the DOPC monolayer. A full un-
derstanding of the extent of interaction, however, is only 
obtained by analyzing the LoD values which depend also 
on the slope of the calibration curves (see experimental). 
The interaction of the silver complexes with DOPC is irre-
versible as the RCVs of the DOPC do not return to the orig-
inal state after electrolyte flushing. In general, the silver 
complex-DOPC interaction appears to have little to do 
with their rather low log P values and is more associated 
with their structure, where the clotrimazole group clearly 
promotes lipid monolayer interaction through its aroma-
ticity. 
The model membrane experiments have been carried out 
previously with an extensive series of compounds includ-
ing tricyclic antidepressant pharmaceuticals,47 aromatic 
hydrocarbons,62 flavonoids,63 ionic liquids,64 nano-
material65 and biomembrane active59 and inactive66 pep-
tides.  Significantly this study is the first one carried out on 
the interaction of organometallic compounds with the  
 
Figure 5. RCVs recorded at 40 V s-1 of a DOPC coated Pt/Hg electrode (black). In the presence of 50 μM of silver(I)-NHC complex 
(left) or clotrimazole-derived imidazolium salt (right) (red). Recovery of DOPC (blue) in PBS at pH 7.4. In the presence of 2 mM of 
cisplatin or AgNO3 (red) in PBS at pH 7.4 (bottom). 
Compound LoD (µM) IC50 ±SD (µM) 
4a 0.002 7.1 ± 3.67 
4e 0.001 1.9 ± 0.74 
5d 0.3 13.8 ± 1.77 
5e 0.07 6.5 ± 4.55 
6a 0.05 10.0 ± 6.79 
6e 0.025 20.5 ± 12.58 
Table 2. LoDs using phospholipid sensing device and IC50 
values towards Panc 10.05 cancerous cell line. 
phospholipid sensor element although metal ion interac-
tions with the element have already been investigated.67   
The clear conclusion from previous studies is that the elec-
trochemical model membrane platform is responsive to 
any species which is biomembrane active. Biomembrane 
activity indicates any interaction which alters the struc-
ture and organization of a biomembrane and can be, but 
not always is, related to lipophilicity.62 Generally the inter-
action is due to an association with the phospholipid polar 
groups and/or phospholipid hydrocarbon tails of the 
phospholipid bilayer. RCVs of the imidazolium ligand pre-
cursors tested demonstrate interactions with DOPC simi-
lar to those observed for the silver complexes (Figure 5, 
right), with the identical structure-based interaction of 
variations in N-substituents and presence/absence of 
chloride on the triphenyl group. Comparing interactions of 
ligand precursors to their corresponding silver complexes 
generally shows a slight decrease in the interactions of the 
imidazolium salts from the interactions of the silver com-
plexes. However, most interestingly, the interaction of the 
clotrimazole ligand precursors, unlike that of the derived 
silver-NHC complexes, tends to be reversible, where the 
RCVs of the DOPC return in most cases almost to the orig-
inal state. In the PBS electrolyte, Cl-  is the common ion 
where the ligand counterion  is Cl-. In the case where the 
ligand counterion is I-, it is unlikely that the electrolyte Cl- 
replaces the very much more polarisable I-  where there 
will be an element of ion pairing with the aromatic ligand 
cation. The evidence shows that the nature of the counter-
ion appears to affect the interaction and reversibility of the ligand cation’s interaction with the model membrane 
as shown by compounds 1e and 2e respectively (Figure  
5). This difference in interaction would not be observed if 
the counterion I- was replaced by Cl-. Interestingly, neither 
cisplatin nor AgNO3 interact with DOPC (Figure 5, bot-
tom). This supports the knowledge of the contribution of 
a copper influx transporter in mediating the accumulation 
of cisplatin in the cell.68 The fact that AgNO3 does not in-
teract with the lipid sensor element indicates that the sil-
ver-NHC interaction is a function of its organically bound 
environment. We note that this study was focused on the 
synthesis, cytotoxicity and  putative anti-cancer activity of 
clotrimazole silver complexes. The ligand precursor 
biomembrane activity was investigated together with that 
of the silver complexes to obtain a better  understanding 











































































The interaction of these complexes with the DOPC coated 
Hg follows received wisdom in that the chloride on the tri-
phenyl group promotes interaction. The rather surprising 
observations are that the polar hydroxyethyl N-substitu-
ent also promotes interaction, and that the inserted Ag 
atom causes the interaction with the lipid layer to become 
irreversible. Such irreversibility has been seen before 
from interactions of the DOPC sensor element with hydro-
phobic substituted benzene compounds and with the 
more polar amine narcotics.62 Observation of the effect of 
the interactions on the capacitance current-potential 
curves is interesting. Both the ligand precursors and sil-
ver-NHC complexes induce a depression of the capaci-
tance current peaks and a positive potential peak shift on 
initial interaction. This is likely due to the positively 
charged ligand precursors and the partially positive Ag 
atom being located within the lipid polar group region.62 
With no increase in the capacitance current baseline, no 
penetration of the apolar region is indicated.  Where a 
stronger interaction is noted (4e and 2d), a significant in-
crease in the capacitance current baseline is more indica-
tive of a complete disruption of the monolayer organiza-
tion which, in the case of the ligand precursor (2d), inter-
action is partly reversible. Also noted is the interaction of 
compounds containing iodides (6a, 6c, 1a and 1c) with 
the DOPC sensor element causing a slight but significant 
hump in the capacitance current baseline (see SI) which 
presumably is the effect of the iodide moiety penetrating 
the monolayer. 
From the LoD values of the complexes on the DOPC sensor 
element (Table 2), 4e has the lowest value of 0.001 µM and 
5d has the highest value of 0.3 µM. Interestingly, 4e also 
exhibits low IC50 values of 1.9 ± 0.74 µM showing a cyto-
toxicity against Panc 10.05 superior to the other com-
plexes tested, and comparable to the IC50 of cisplatin (1.7 
± 0.41 µM). 5d on the other hand has a relatively high IC50 
value of 13.8 ± 1.77 µM. The data implies that several fac-
tors, in addition to lipid biomembrane damage, contribute 
to the cytotoxicity of the silver complexes. 
CONCLUSIONS: Thirteen clotrimazole based silver(I)-NHC 
complexes have been synthesized and fully characterized. 
The antiproliferative activities of the silver complexes 
were examined against pancreatic adenocarcinoma cell 
line Panc 10.05 and non-cancerous retinal epithelial cells 
ARPE-19 and compared to cisplatin. Selected complexes 
were also examined against pancreatic adenocarcinoma 
cell line MIA PaC-2 and colorectal carcinoma BE. Whilst 
most of the complexes were less potent than cisplatin 
against Panc 10.05, complex 4e showed comparable po-
tency to cisplatin in addition to showing 5-fold greater se-
lectivity than cisplatin to Panc 10.05 over the non-cancer-
ous ARPE-19. Complexes 5e and 4a also showed im-
proved selectivity towards Panc 10.05 over cisplatin. 4e 
and 5e exhibit “intermediated lipophilicity” where the 
complex contains both a hydrophobic and a hydrophilic 
group which plays a role in both cytotoxicity and selectiv-
ity. The hydrophilic part, which in these complexes is the 
hydroxyethyl, increases their water solubility improving 
their transfer at the biointerface, while the hydrophobic 
triphenyl group promotes an interaction with the lipid bi-
layers of membranes. While the chloride containing 
groups 4 and 5 appear to be consistent in their cytotoxi-
city trends, iodide containing complexes 6a, 6c and 6e 
show different trends in cytotoxicity across the different 
cancerous cell lines, indicating that their activity is tumor-
type dependent. The introduction of a silver atom to the 
clotrimazole-derived compounds renders their interac-
tion with an electrode-supported DOPC sensor element ir-
reversible. The heterocyclic N-substituted hydroxyethyl 
chain and a chloride atom on the triphenyl group en-
hances the activity of the ligand precursors and the sil-
ver(I)-NHC complexes with the DOPC sensor element. The 
silver complex showing the strongest interaction with the 
biomembrane-like sensor element had an IC50 value very 
close to that of cisplatin. These results help validate this 
electrochemical platform as an early stage screen i.e. prior 
to cell studies, for candidate pharma where the mode-of-
action is structure related and lipid membrane-based. 
EXPERIMENTAL SECTION 
General Methods. Where stated, manipulations were 
performed under an atmosphere of dry nitrogen by means 
of standard Schlenk line techniques. Anhydrous solvents 
were prepared by passing the solvent over activated alu-
mina to remove water, copper catalyst to remove oxygen 
and molecular sieves to remove any remaining water, via 
the Dow-Grubbs solvent system. 1H and 13C{1H} NMR spec-
tra were recorded on either a Bruker DPX300 or a Bruker 
AV500 spectrometer. The values of chemical shifts are 
given in ppm and values for coupling constants (J) in Hz. 
Mass spectra were collected on a Bruker Daltonics (micro 
TOF) instrument operating in the electrospray mode. Mi-
croanalyses were performed using a Carlo Erba Elemental 
Analyzer MOD 1106 spectrometer. X-ray diffraction data 
were collected on either a Bruker Nonius X8 diffractome-
ter fitted with an Apex II detector with Mo-Kα radiation (λ 
= 0.71073 Å), or an Agilent SuperNova diffractometer fit-
ted with an Atlas CCD detector with Mo-Kα radiation (λ = 0.71073 Å) or Cu Kα radiation (λ = 1.5418 Å). Crystals 
were mounted under oil on glass or nylon fibers. Data sets 
were corrected for absorption using a multiscan method, 
and the structures were solved by direct methods using 
SHELXS-97 and refined by full-matrix least squares on F2 
using ShelXL-97.69-70 Molecular graphics for all structures 
were generated using POV-RAY in the X-Seed program. 
Synthesis of imidazolium iodide 1a. Clotrimazole (0.20 
g, 0.58 mmol) and methyl iodide (0.72 mL, 11.60 mmol) 
were dissolved in dichloromethane (3 mL) and heated to 
45 °C in the microwave for 15 minutes with stirring. Di-
ethyl ether was added to the resulting pale yellow solu-
tion, which induced precipitation of the product as an off-
white solid. This was filtered, washed with diethyl ether, 
and dried in vacuo. Yield: 0.21 g (75 %). 1H NMR (CDCl3, 300 MHz) δ: 9.10 (s, 1H, NCHN), 7.75 (s, 1H, NCH), 7.50-
7.11 (m, 14H, aromatic), 6.95 (s, 1H, NCH), 4.25 (s, 3H, 
CH3). 13C{1H} NMR (CDCl3, 75 MHz) δ: 138.0 (CH), 137.9 
(C), 137.4 (C), 135.1 (C), 132.9 (CH), 131.7 (CH), 131.5 
(CH), 130.1 (CH), 192.5 (CH), 129.2 (CH), 128.1 (CH), 
124.1 (CH), 123.6 (CH), 79.5 (C), 38.8 (CH3). HRMS (ESI+): 
Calcd. for C23H20ClN2 [M-I]+: 359.1310. Found: 359.1311. 
C23H26ClIN2.1/3H2O: C, 56.06; H, 4.23; N, 5.68. Found: C, 
56.00; H, 4.10; N, 5.70. Single crystals suitable for X-ray 
diffraction analysis were grown by the vapor diffusion of 





Synthesis of imidazolium iodide 1c. Clotrimazole (0.20 
g, 0.58 mmol) and butyl iodide (0.67 mL, 5.80 mmol) were 
dissolved in dichloromethane (3 mL) and heated to 45 °C 
in the microwave for 15 minutes with stirring. Diethyl 
ether was added to the resulting pale yellow solution, 
which induced precipitation of the product as a white 
solid.  This was filtered, washed with diethyl ether, and 
dried in vacuo. Yield: 0.18 g (59 %). 1H NMR (CDCl3, 300 MHz) δ: 9.18 (s, 1H, NCHN), 7.71(s, 1H, NCH), 7.51-6.91 
(m, 14H, aromatic), 6.74 (s, 1H, NCH), 4.63 (t, J = 7.3 Hz, 
2H, CH2), 1.86 (m, 2H, CH2), 1.37 (m, 2H, CH2), 0.93 (t, J = 
7.3 Hz, 3H, CH3). 13C{1H} NMR (CDCl3, 75 MHz) δ: 140.3 (C), 
138.1 (C), 137.1 (CH), 135.5 (C), 132.1 (CH), 131.4 (CH), 
130.0 (CH), 129.7 (CH), 129.0 (CH), 127.9 (CH), 127.0 
(CH), 123.6 (CH), 121.5 (CH), 79.1 (C), 50.9 (CH2), 32.3 
(CH2), 19.2 (CH2), 13.5 (CH3). HRMS (ESI+): Calcd. for 
C26H26ClN2 [M-I]+: 401.1785. Found: 401.1778. Anal. Calcd 
for C26H24ClIN2.1/2H2O: C, 58.06; H, 5.06; N, 5.21. Found: 
C, 58.30; H, 4.90; N, 5.30. Single crystals suitable for X-ray 
diffraction analysis were grown by the vapor diffusion of 
diethyl ether into a concentrated solution of the product 
in dichloromethane. 
Synthesis of imidazolium iodide 1e. Clotrimazole (0.50 
g, 1.45 mmol) and iodoethanol (0.23 mL, 2.9 mmol) were 
dissolved in dichloromethane (3 mL) and heated at reflux 
under nitrogen for 48 hours resulting in a brown solution. 
Addition of ethyl acetate precipitated a yellow solid which 
was filtered and washed with ethyl acetate. Trituration 
with acetone gave the product as a white solid. Yield: 0.38 
g (47 %). 1H NMR (CDCl3, 300 MHz) δ: 9.04 (s, 1H, NCHN), 
7.75 (s, 1H, NCH), 7.52-7.10 (m, 14H, aromatic), 7.02 (s, 
1H, NCH), 4.64 (t, J = 4.9 Hz, 2H, CH2), 3.99 (t, J = 4.9 Hz, 
2H, CH2), 2.82 (broad s, 1H, OH). 13C{1H} NMR (CDCl3, 75 MHz) δ: 138.1 (C), 137.8 (CH), 137.4 (C), 135.3 (C), 133.0 
(CH), 131.5 (CH), 131.4 (CH), 130.0 (CH), 129.5 (CH), 
129.2 (CH), 128.1 (CH), 123.5 (CH), 123.4 (CH) 79.3 (C), 
59.9 (CH2), 52.8 (CH2). HRMS (ESI+): Calcd. for 
C24H22ClN2O [M-I]+: 389.1421. Found: 389.1419. Calcd for 
C24H22ClIN2O: C, 55.78; H, 4.29; N, 5.42. Found: C, 56.00; H, 
4.40; N, 5.90. Single crystals suitable for X-ray diffraction 
analysis were grown by the vapor diffusion of diethyl 
ether into a concentrated solution of the product in meth-
anol. 
Synthesis of imidazolium chloride 2a. 2-Chlorotrityl 
chloride (0.50 g, 1.60 mmol) and 1-methylimidazole (0.50 
ml, 6.27mmol) were dissolved in acetonitrile (10 mL) and 
heated at reflux for 24 hours. The solution was allowed to 
cool to room temperature and the product was precipi-
tated as a white solid using diethyl ether. Yield: 0.53 g (85 
%). 1H NMR (CDCl3, 300 MHz) δ: 9.10 (s, 1H, NCHN), 7.75 
(s, 1H, NCH), 7.50-7.11 (m, 14H, aromatic), 6.95 (s, 1H, 
NCH), 4.25 (s, 3H, CH3). 13C{1H} NMR (CDCl3, 75 MHz) δ: 
139.1 (CH), 138.4 (C), 137.6 (C), 135.4 (C), 133.0(CH), 
131.7 (CH), 131.4 (CH), 130.0 (CH), 129.5 (CH), 129.1 
(CH), 127.9 (CH), 123.7 (CH), 123.4 (CH), 79.3 (C), 37.8 
(CH3). HRMS (ESI+): Calcd. for C23H20ClN2 [M-Cl]+: 
359.1310. Found: 359.1311. Single crystals suitable for X-
ray diffraction analysis were grown by the vapor diffusion 
of pentane into a concentrated solution of the product in 
dichloromethane. 
Synthesis of imidazolium chloride 2b. 2-Chlorotrityl 
chloride (0.50 g, 1.60 mmol) and 1-allylimidazole (0.48 
mL, 4.40 mmol) were dissolved in acetonitrile (10 mL) 
and heated at reflux for 24 hours. The yellow solution was 
allowed to cool to room temperature and a yellow oil 
formed on addition of diethyl ether. The solution was de-
canted from the oil which was washed with ethyl acetate 
and triturated with acetone to give the product as a white 
solid that was dried in vacuo. Yield: 0.37 g (55 %). 1H NMR 
(CDCl3, 300 MHz) δ: 9.84 (s, 1H, NCHN), 7.71 (s, 1H, NCH), 
7.51-7.06 (m, 14H, aromatic), 6.96 (s, 1H, NCH), 6.08-5.95 
(m, 1H, CH), 5.41-5.35 (m, 4H, N-CH2CHCH2). 13C{1H} NMR 
(CDCl3, 75 MHz) δ: 138.8 (CH), 138.4 (C), 137.5 (C), 135.4 
(C), 132.9 (CH), 131.8 (CH), 131.5 (CH), 130.8 (CH), 130.0 
(CH), 129.5 (CH),129.1 (CH), 127.9 (CH), 123.5 (CH), 122.2 
(CH), 121.9 (CH2) 79.4 (C), 52.9 (CH2). HRMS (ESI+): Calcd. 
for C25H22ClN2 [M-Cl]+: 385.1466. Found: 385.1471. Single 
crystals suitable for X-ray diffraction analysis were grown 
by the vapor diffusion of diethyl ether into a concentrated 
solution of the product in dichloromethane. 
Synthesis of imidazolium chloride 2c. 2-Chlorotrityl 
chloride (0.50g, 1.60 mmol) was dissolved in dichloro-
methane (5 mL) and 1-butylimidazole (0.21 mL, 1.60 
mmol) was added. The mixture was transferred to an am-
poule and heated at 45 °C for 24 hours in a closed system. 
Excess diethyl ether was added to the resulting yellow so-
lution to obtain a white solid. Yield: 0.30 g (43 %). 1H NMR 
(CDCl3, 300 MHz) δ: 9.60 (s, 1H, NCHN), 8.19 (s, 1H, NCH), 
7.47-6.98 (m, 15H, aromatic & NCH), 4.63 (t, 2H, CH2), 1.84 
(pent, 2H, CH2), 1.28 (sext, 2H, CH2), 0.86 (t, 3H, CH3). 
13C{1H} NMR (CDCl3, 75 MHz): δ 138.5 (C), 138.2 (CH), 
137.5 (C), 135.3 (C), 132.9 (CH), 131.8 (CH), 131.4 (CH), 
129.8 (CH), 129.3 (CH), 129.0 (CH), 127.9 (CH), 123.6 
(CH), 122.7 (CH), 79.1 (C), 50.5 (CH2), 32.5 (CH2), 19.4 
(CH2), 13.6 (CH3). HRMS (ESI+): Calcd. for C26H26ClN2 [M-
Cl]+: 401.1779. Found: 401.1764. Anal. Calcd for 
C26H26Cl2N2: C, 71.39; H, 5.99; N, 6.90. Found: C, 71.10; H, 
6.20; N, 6.60. 
Synthesis of imidazolium chloride 2d. 2-Chlorotrityl 
chloride (0.50 g, 1.60 mmol) and 1-benzylimidazole (0.25 
mL, 1.93 mmol) were dissolved in acetonitrile (10 mL) 
and heated at reflux for 24 hours. The solution was al-
lowed to cool to room temperature and a yellow solid was 
precipitated using diethyl ether. This was filtered and 
washed with ethyl acetate and acetone to give a white 
solid which was dried in vacuo. Yield: 0.14 g (20 %). 1H 
NMR (CDCl3, 300 MHz) δ: 9.92 (s, 1H, NCHN), 7.49 (s, 1H, 
NCH), 7.44-7.02 (m, 19H, aromatic), 6.88 (s, 1H, NCH), 
5.90 (s, 2H, CH2). 13C{1H} NMR (CDCl3, 75 MHz) δ: 157.7 
(C), 138.9 (CH), 138.5 (C), 137.5 (C), 135.4 (C), 133.7 (CH), 
132.9 (CH), 131.9 (CH), 131.4 (CH), 129.9 (CH),129.4 (CH), 
129.3 (CH), 129.1 (CH), 129.1 (CH), 127.9 (CH), 123.5 
(CH), 122.1 (C), 79.3 (CH2), 54.1 (CH2). HRMS (ESI+): 
Calcd. for C29H24ClN2 [M-Cl]+: 435.1623. Found: 435.1630. 
Single crystals suitable for X-ray diffraction analysis were 
grown by the vapor diffusion of diethyl ether into a con-
centrated solution of the product in dichloromethane. 
Synthesis of imidazolium chloride 2e. 2-Chlorotrityl 
chloride (1.0 g, 3.20 mmol) was dissolved in dichloro-
methane (5 mL) in an ampoule to which 1-(2-hydroxy-
ethyl) imidazole (0.30 mL, 3.20 mmol) was added. The so-
lution was heated to 45 °C for 24 hours in a closed system. 
Excess pentane was added to the yellow solution yielding 




methanol-pentane to obtain a yellow solid. Yield: 1.32 g 
(97 %). 1H NMR (d6-acetone, 300 MHz): δ 8.98 (s, 1H, 
NCHN),  7.68 (s, 1H, NCH), 6.91 (s, 1H, NCH), 7.87-7.12 (m, 
14H, aromatic), 4.41 (t, J = 12 Hz, 2H, CH2), 3.87 (t, J = 12 
Hz, 2H, CH2). 1H NMR (d4-MeOD, 300 MHz): δ 9.00 (s, 1H, 
NCHN),  7.83 (s, 1H, NCH), 7.64-7.20 (m, 15H, aromatic & 
NCH), 4.41 (t, 2H, CH2), 3.89 (t, 2H, CH2). 13C{1H} NMR (d6-
acetone, 125 MHz): δ 139.0 (C), 138.2 (CH), 135.4 (C), 
133.2 (C), 132.1 (CH), 131.8 (CH), 130.4 (CH), 129.8 (CH), 
129.3 (CH), 128.5 (CH), 127.8 (CH), 124.6 (CH), 123.8 
(CH), 120.6 (C), 79.2 (C), 61.6 (CH2), 60.2 (CH2). HRMS 
(ESI+): Calcd. for C24H22ClN2O [M-Cl]+: 389.1421. Found: 
389.1425. Anal. Calcd for C24H22Cl2N2O1/4H2O: C, 67.06; 
H, 5.28; N, 6.52. Found: C, 67.20; H, 5.25; N, 6.70. Single 
crystals suitable for X-ray diffraction analysis were grown 
by the vapor diffusion of diethyl ether into a concentrated 
solution of the product in methanol. 
Synthesis of imidazolium chloride 3a. Trityl chloride 
(6.80 g, 24.40 mmol) and 1-methylimidazole (2 g, 24.40 
mmol) were dissolved in acetonitrile (20 mL) and heated 
at reflux for 24 hours. The solution was allowed to cool 
and a white solid was obtained with the addition of excess 
diethyl ether. Yield: 6.1 g, (69 %). 1H NMR (300 MHz, 
CDCl3): δ 9.50 (s, 1H, NCHN), 7.90 (s, 1H, NCH), 7.42-7.12 
(m, 15H, aromatic), 6.97 (s, 1H, NCH), 4.29 (s, 3H, CH3). 
13C{1H} NMR (125 MHz, CDCl3): δ 147.0 (CH), 139.6 (CH), 
138.0 (CH), 135.9 (CH), 129.7 (CH), 129.3 (CH), 129.0 
(CH), 128.0 (CH), 127.9 (CH), 127.2 (CH), 124.1 (CH), 
123.8 (CH), (CH), 122.1 (CH), 119.9 (CH), 79.5 (C), 36.2 
(CH3). HRMS (ESI+): Calcd. for C23H21N2 [M-Cl]+: 325.1699. 
Found: 325.1701. Anal. Calcd for C23H21ClN2.2H2O: C, 
69.60; H, 6.35; N, 7.06. Found: C, 69.80; H, 6.30; N, 7.40. 
Synthesis of imidazolium chloride 3b. Trityl chloride 
(5.15 g, 18.50 mmol) and 1-allyl-1H-imidazole (0.58 g, 
1.49 mmol) were dissolved in dichloromethane (20 mL) 
and heated at reflux for 24 hours. Addition of excess di-
ethyl ether gave a white solid that was dried in vacuo. 
Yield: 3.03 g, (42 %). 1H NMR (300 MHz, CDCl3): δ 9.62 (s, 
1H, NCHN), 7.81 (s, 1H, NCH), 7.41-7.11 (m, 15H, aro-
matic), 6.98 (s, 1H, NCH), 6.10-5.97 (m, 1H, CH), 5.43-5.35 
(m, 4H, N-CH2CHCH2). 13C{1H} NMR (125 MHz, CDCl3): δ 
139.6 (CH), 138.5 (C), 138.0 (CH), 130.6 (CH), 130.3 (CH), 
129.6 (CH), 129.6 (CH), 129.1 (CH), 128.9 (CH), 128.6 
(CH), 127.9 (CH), 127.6 (CH), 126.6 (CH), 126.4 (CH), 
125.7 (CH), 123.8 (CH), 122.2 (CH2), 52.8 (CH2). HRMS 
(ESI+): Calcd. for C25H23N2 [M-Cl]+: 351.1856. Found: 
351.4187. Anal. Calcd for C25H23ClN2: C, 72.02; H, 6.37; N, 
6.72. Found: C, 71.80; H, 6.30; N, 6.90. 
Synthesis of imidazolium chloride 3c. Trityl chloride 
(1.35 g, 4.84 mmol) and 1-butylimidazole (0.60 g, 4.84 
mmol) were dissolved in dichloromethane (20 mL) and 
heated at reflux for 24 hours. Excess diethyl ether was 
added to the solution to obtain an off white solid. A satu-
rated solution of NaHCO3 (20 mL) was added to the solid 
and the product was extracted into dichloromethane (3 x 
20 mL). Recrystallization from dichloromethane/diethyl 
ether yielded a white solid which was dried in vacuo. Yield: 
0.99 g (51 %). 1H NMR (300 MHz, CDCl3): δ 9.46 (s, 1H, 
NCHN), 7.99 (s, 1H, NCH), 7.43-7.03 (m, 15H, aromatic), 
7.01 (s, 1H, NCH), 4.69 (t, 2H, CH2), 1.85 (q, 2H, CH2), 1.31 
(sext, 2H, CH2), 0.97 (t, 3H, CH3). 13C{1H}  NMR (75 MHz, 
CDCl3): δ 139.6 (CH), 138.1 (C), 137.6 (CH), 136.3 (CH), 
135.3 (CH), 133.5 (CH), 131.3 (CH), 130.4 (CH), 129.6 
(CH), 129.3 (CH), 128.9 (CH), 127.7 (CH), 126.3 (CH), 
125.7 (CH), 124.3 (Ar), 123.9, (CH), 50.5 (CH2), 32.3 (CH2), 
19.5 (CH2), 13.5 (CH3). HRMS (ESI+): Calcd. for C26H27N2 
[M-Cl]+: 367.2169. Found: 367.2119. Anal. Calcd for 
C26H27ClN2.4/3H2O: C, 73.14; H, 7.00; N, 6.56. Found: C, 
73.10; H, 6.90; N, 6.80. 
Synthesis of imidazolium chloride 3d. Trityl chloride 
(0.50 g, 1.79 mmol) and 1-benzylimidazole (0.28 g, 1.79 
mmol) were dissolved in dichloromethane (5 mL). The so-
lution was transferred to an ampoule and heated at 45 °C 
for 24 hours in a closed system. Excess diethyl ether was 
added to the solution to acquire an off white solid which 
was filtered and dried in vacuo. A saturated solution of Na-
HCO3 (20 mL) was added to the solid and the product was 
extracted into dichloromethane (3 x 20 mL).  Excess di-
ethyl ether was added to the solution furnishing a white 
solid which was dried in vacuo. Yield: 0.51 g  (71 %). 1H 
NMR (500 MHz, CDCl3): δ 9.82 (s, 1H, NCHN),  7.71 (s, 1H, 
NCH), 6.93 (s, 1H, NCH), 7.46-7.11 (m, 20H, aromatic), 
5.94 (s, 2H, CH2). 13C{1H} NMR (75 MHz, CDCl3): δ 138.2 
(CH), 135.5 (C), 129.6 (CH), 129.5 (CH), 129.4 (CH), 129.3 
(CH), 129.2 (CH), 128.9 (CH), 127.9 (CH), 127.2 (CH), 
123.7 (CH), 122.0 (CH), 121.0 (CH), 52.93 (CH2). HRMS 
(ESI+): Calcd for C29H25N2 [M-Cl]+: 401.2012. Found: 
401.2016. Anal. Calcd for C29H25ClN2.H2O: C, 76.55; H, 5.98; 
N, 6.16. Found: C, 76.10; H, 5.90; N, 6.60. 
Synthesis of imidazolium chloride 3e. Trityl chloride 
(0.50 g, 1.80 mmol) was dissolved in dichloromethane (5 
mL) in an ampoule to which 1-(2-hydroxyethyl) imidazole 
(0.17 mL, 1.80 mmol) was added. The solution was heated 
to 45 °C for 72 hours in a closed system. White solid pre-
cipitated out of the solution, which was filtered off and re-
crystallized from methanol/pentane obtaining a white 
solid that was further dried in vacuo. Yield: 0.66 g (94 %). 
1H NMR (300 MHz, d4-MeOD): δ 8.89 (s, 1H, NCHN),  8.24 
(s, 1H, NCH), 7.79 (s, 1H, NCH), 7.50-7.24 (m, 15H, aro-
matic), 4.37 (t, 2H, J = 10.5 Hz, CH2), 4.24 (t, 2H, J = 10.5 Hz, 
CH2). 13C{1H} NMR (300 MHz, d4-MeOD): δ 141.4 (C), 139.4 
(C), 130.8 (CH), 130.3 (CH), 129.9 (CH), 125.5 (CH), 123.9 
(CH), 60.9 (CH2), 53.5 (CH2). HRMS (ESI+): Calcd for 
C24H23N2O [M-Cl]+: 355.1810. Found: 355.1813. Anal. 
Calcd for C24H23ClN2O.4/3H2O: C, 69.47; H, 6.23; N, 9.00; 
found: C, 69.00; H, 6.00; N, 9.26. Single crystals suitable for 
X-ray diffraction analysis were grown by the vapor diffu-
sion of diethyl ether into a concentrated solution of the 
product in methanol. 
Synthesis silver complex 4a. Imidazolium salt 2a (0.50 
g, 1.27 mmol) and silver oxide (0.29 g, 1.27 mmol) were 
dissolved in dichloromethane (10 mL) and heated at re-
flux for 24 hours in the dark. The mixture was allowed to 
cool and filtered over Celite, with the solid being washed 
with dichloromethane. The solvent was removed from the 
filtrate and the solid dried in vacuo to give the product as 
a white crystalline solid. Yield: 0.39 g  (62 %). 1H NMR 
(300 MHz, CDCl3): δ 7.44-7.42 (m, 2H, NCH & aromatic), 
7.36-7.09  (m, 14H, aromatic), 6.95 (m, 1H, NCH), 3.88 (s, 
3H, CH3). 13C{1H} NMR (75MHz, CDCl3): δ 140.9 (C), 140.0 
(C), 135.7 (C), 132.5 (CH), 131.5 (CH), 130.6 (CH), 130.5 
(CH), 128.4 (CH), 128.1 (CH), 127.8 (CH), 123.6 (CH), 
119.7 (CH), 77.7 (C), 40.2 (CH3). HRMS (ESI+): Calcd for 




Anal. Calcd for C23H19AgCl2N2.2/3CH2Cl2: C, 50.87; H, 3.67; 
N, 5.01. Found: C, 50.90; H, 4.10; N, 4.60. 
Synthesis silver complex 4b. Imidazolium salt 2b (0.30 
g, 0.71 mmol) and silver oxide (0.17 g, 0.71 mmol) were 
dissolved in dichloromethane (8 mL) and heated at reflux 
for 24 hours in the dark. The mixture was allowed to cool 
and filtered over Celite, with the solid being washed with 
dichloromethane. The solvent was removed from the yel-
low filtrate and the solid dried in vacuo to give the product 
as a white solid. Yield: 0.14 g, (38 %). 1H NMR (300 MHz, 
CDCl3): δ 7.36-7.04 (m, 15H, aromatic & NCH), 6.88 (s, 1H, 
NCH), 5.87 (m, 1H, N-CH2CHCH2), 5.24-5.12 (m, 2H, N-
CH2CHCH2), 4.71 (d, 2H, N-CH2CHCH2). 13C{1H} NMR (125 
MHz, CDCl3): δ 139.9 (C), 135.8 (C), 132.7 (CH), 132.6 
(CH), 131.7 (CH), 130.7 (CH), 130.6 (C), 128.5 (CH), 128.2 
(CH), 128.0 (CH), 123.9 (CH), 119.5 (CH),  118.5 (CH2), 
77.6 (C), 55.6 (CH2). HRMS (ESI+): Calcd for C50H44AgCl2N4 
[2M-AgCl2]+: 877.1834. Found: 877.1830. Anal. Calcd for 
C25H21AgCl2N2.1/2H2O: C, 55.89; H, 4.13; N, 5.21. Found: C, 
55.50; H, 4.20; N, 5.00.  
Synthesis of silver complex 4c. Imidazolium salt 2c 
(0.02 g, 0.05 mmol) and silver oxide (0.006 g, 0.03 mmol) 
were dissolved in a mixture of anhydrous methanol (3 
mL) and dichloromethane (3 mL) in a Schlenk flask.  The 
mixture was stirred at room temperature for 24 hours in 
the dark. The mixture was filtered over Celite and the sol-
vent removed from the filtrate in vacuo to yield the prod-
uct as a light yellow solid. Yield: 0.005 g (20 %). 1H NMR 
(300 MHz, CDCl3): δ 7.61-6.88 (m, 16H, aromatic & NCH), 
4.15 (t, 2H, N-CH2CH2CH2CH3), 1.83 (m, 2H, N-
CH2CH2CH2CH3), 1.57 (m, 2H, N-CH2CH2CH2CH3), 0.92 (m, 
3H, N-CH2CH2CH2CH3). 13C{1H} NMR (75 MHz, CDCl3): δ 
141.2 (C), 139.6 (C), 138.4 (CH), 135.4 (C), 132.4 (CH), 
131.4 (CH), 130.3 (CH), 129.7 (CH), 129.0 (CH), 128.4 
(CH), 128.1 (CH), 127.8 (CH), 123.6 (CH), 118.2 (CH), 77.4 
(C), 53.2 (CH2), 33.2 (CH2), 19.5 (CH2), 13.7 (CH3). HRMS 
(ESI+): Calcd for C52H50AgCl2N4 [2M-AgCl2]+: 909.2460. 
Found: 909.2609. Anal. Calcd for C130H125Ag4Cl9N10 i.e. 3:1 
Ag(NHC)Cl:[Ag(NHC)2]Cl: C, 60.57; H, 4.89; N, 5.43. Found: 
C, 60.80; H, 4.80; N, 5.10. 
Synthesis of silver complex 4d. Imidazolium salt 2d 
(0.10 g, 0.21 mmol) and silver oxide (0.05 g, 0.21 mmol) 
were dissolved in dichloromethane (8 mL) and heated at 
reflux for 24 hours in the dark. The mixture was filtered 
over Celite with the solid being washed with dichloro-
methane, and the solvent removed from the filtrate. The 
solid was dried in vacuo to give the product as an off white 
solid. Yield: 0.06 g (50 %). 1H NMR (300 MHz, CDCl3): δ 
7.46-7.10 (m, 20H, aromatic & NCH), 6.87 (s, 1H, NCH), 
5.35 (s, 2H, CH2). 13C{1H} NMR (75 MHz, CDCl3): δ 141.0 
(C), 139.9 (C), 135.8 (C), 135.6 (C), 132.7 (CH), 131.7 (CH), 
130.7 (CH), 129.2 (CH), 128.8 (CH), 128.6 (CH),128.2 (CH), 
128.1 (CH), 127.8 (CH), 127.1 (CH), 78.0 (C), 57.2 (CH2). 
HRMS (ESI+): Calcd for C58H46AgCl2N4 [2M-AgCl2]+: 
977.2147. Found: 977.2170. Anal. Calcd for C29H23AgCl2N2. 
2H2O: C, 56.70; H, 4.43; N, 4.56. Found: C, 56.80; H, 4.60; N, 
4.10. 
Synthesis of silver complex 4e. Imidazolium salt 2e (0.2 
g, 0.47 mmol) and silver oxide (0.065 g, 0.28 mmol) were 
dissolved in a solvent mixture of anhydrous methanol (10 
mL) and anhydrous dichloromethane (5 mL) in a Schlenk 
flask with 4Å activated molecular sieves. The mixture was 
stirred at room temperature for 24 hours in the dark. The 
mixture was filtered over Celite and the solvent removed 
from the filtrate in vacuo to yield the product as a white 
solid. Yield: 0.13 g (56 %). 1H NMR (300 MHz, d4-MeOD): δ 7.52-6.99 (m, 16H, aromatic & NCH), 3.65-3.60 (m, 4H, 
CH2). 13C{1H} NMR (75 MHz, d4-MeOD): δ 142.3 (C), 141.6 
(C), 137.2 (C), 133.8 (CH), 132.5 (CH), 131.9 (CH), 131.6 
(CH), 129.6 (CH), 129.1 (CH), 128.1 (CH), 124.9 (CH), 
120.6 (CH), 78.7 (C), 62.5 (CH2), 56.6 (CH2). HRMS (ESI+): 
Calcd for C48H42AgCl2N4O2 [2M-AgCl2]+: 885.1732. Found: 
885.1747. Anal. Calcd for C48H42AgCl3N4O2: C, 62.59; H, 
4.60; N, 6.08. Found: C, 63.20; H, 5.30; N, 5.90. Single crys-
tals suitable for X-ray diffraction analysis were grown by 
the vapor diffusion of diethyl ether into a concentrated so-
lution of the product in methanol. 
Synthesis silver complex 5a. Imidazolium salt 3a (0.50 
g, 1.38 mmol) and silver oxide (0.32 g, 1.38 mmol) were 
dissolved in dichloromethane (30 mL) and heated at re-
flux for 18 hours in the dark. The mixture was filtered over 
Celite and the solvent removed from the filtrate in vacuo 
to give a brown solid. Recrystallization from dichloro-
methane/diethyl ether yielded the product as a white 
solid. Yield: 0.4 g (62 %). 1H NMR (300 MHz, CDCl3): δ 
7.34-7.20 (m, 15H, aromatic), 7.04 (s, 1H, NCH), 6.98 (s, 
1H, NCH), 3.84 (s, 3H, CH3). 13C{1H} NMR (75 MHz, CDCl3): δ 140.5 (C), 129.6 (CH), 128.5 (CH), 128.2 (CH), 127.9 
(CH), 122.0(HC), 119.8 (CH), 36.12 (CH3). HRMS (ESI+): 
Calcd for C46H40AgN4 [2M-AgCl2]+: 757.2301. Found: 
757.2314. Anal. Calcd for C23H20AgClN2.2/3H2O: C, 57.58; 
H, 4.48; N, 5.84. Found: C, 57.90; H, 4.60; N, 5.40. Single 
crystals suitable for X-ray diffraction analysis were grown 
by the vapor diffusion of diethyl ether into a concentrated 
solution of the product in dichloromethane. 
Synthesis silver complex 5b. Imidazolium salt 3b (0.58 
g, 1.49 mmol) and silver oxide (0.35 g, 1.49 mmol) were 
dissolved in dichloromethane (30 mL) and heated at re-
flux for 18 hours in the dark. The mixture was filtered over 
Celite and the solvent removed from the filtrate in vacuo 
to give a colorless oil. Recrystallization from dichloro-
methane/diethyl ether yielded the product as a white 
solid. Yield: 0.41 g (55 %). 1H NMR (300 MHz, CDCl3): δ 
7.37-7.19 (m, 15H, aromatic), 7.07 (s, 1H, NCH), 6.95 (s, 
1H, NCH), 6.00 (m, 1H, N-CH2CHCH2), 5.24 (m, 2H, N-
CH2CHCH2), 4.75 (d, 2H, N-CH2CHCH2). 13C{1H} NMR (75 
MHz, CDCl3): δ 142.1 (C), 132.6 (NCH), 130.6 (NCH), 129.6 
(CH), 128.9 (CH), 128.6 (CH), 127.7 (CH), 119.5 (HC), 
117.5 (CH2), 55.6 (CH2). HRMS (ESI+): Calcd for 
C50H44AgN4 [2M-AgCl2]+: 809.2614. Found: 809.2616. 
Anal. Calcd for C25H22AgClN2: C, 60.81; H, 4.49; N, 5.67. 
Found: C, 60.61; H, 4.50; N, 5.60. Single crystals suitable 
for X-ray diffraction analysis were grown by the vapor dif-
fusion of diethyl ether into a concentrated solution of the 
product in dichloromethane. 
Synthesis silver complex 5c. Imidazolium salt 3c (0.62 g, 
1.53 mmol) and silver oxide (0.36 g, 1.53 mmol) were dis-
solved in dichloromethane (30 mL) and heated at reflux 
for 18 hours in the dark. The mixture was filtered over 
Celite and the solvent removed from the filtrate in vacuo 
to give a colorless oil. Recrystallization from dichloro-
methane/diethyl ether yielded the product as a white 
solid. Yield: 0.21 g (26 %). 1H NMR (300 MHz, CDCl3): δ 




1H, NCH), 4.13 (t, 2H, CH2), 1.80 (quin, 2H, CH2), 1.31 (sext, 
2H, CH2), 0.93 (t, 2H, CH2). 13C{1H} NMR (75 MHz, CDCl3): δ 147.0 (C), 137.2 (CH), 129.7 (CH), 129.4 (CH), 129.1 
(CH), 128.0 (CH), 127.8 (CH), 124.0 (CH), 122.6 (CH), 79.7 
(C) 50.6 (CH2), 32.4 (CH2), 19.6 (CH2), 13.6 (CH3). HRMS 
(ESI+): Calcd for C52H52AgN4 [2M-AgCl2]+: 841.3240. 
Found: 841.3245. Anal. Calcd for C26H26AgClN2: C, 61.25; 
H, 5.14; N, 5.49. Found: C, 61.60; H, 5.15; N, 5.40. Single 
crystals suitable for X-ray diffraction analysis were grown 
by the vapor diffusion of diethyl ether into a concentrated 
solution of the product in methanol. 
Synthesis silver complex 5d. Imidazolium chloride 3d 
(0.086 g, 0.19 mmol) and silver oxide (0.027 g, 0.12 mmol) 
were dissolved in a mixture of anhydrous methanol (5 
mL) and dichloromethane (5 mL) in a Schlenk flask with 
activated 4Å molecular sieves. The mixture was stirred at 
room temperature for 24 hours in the dark. The mixture 
was filtered over Celite and the solvent removed from the 
filtrate in vacuo to give a light yellow solid. Yield : 0.01 g 
(10 %). 1H NMR (300 MHz, CDCl3): δ 7.45-6.88 (m, 22H, 
aromatic & NCH), 4.54 (s, 2H, CH2). 13C{1H} NMR (125 
MHz, CDCl3): δ 186.6 (C), 184.1 (C), 142.3 (C), 135.8 (C), 
130.1 (CH), 129.9 (CH), 129.0 (CH), 128.5 (CH), 128.3 
(CH), 127.4 (CH), 124.3 (CH), 119.6 (CH), 77.4 (C), 65.9 
(CH2). HRMS (ESI+): Calcd for C58H48AgN4 [2M-AgCl2]+: 
909.2927. Found: 909.2964. Anal. Calcd for 
C232H192Ag5Cl5N16 i.e. 2:3 Ag(NHC)Cl:[Ag(NHC)2]Cl: C, 
71.07; H, 4.94; N, 5.72. Found: C, 70.80; H, 5.30; N, 5.60. 
Single crystals suitable for X-ray diffraction analysis were 
grown by the vapor diffusion of diethyl ether into a con-
centrated solution of the product in dichloromethane. 
Synthesis of silver complex 5e. Imidazolium salt 3e (0.1 
g, 0.26 mmol) and silver oxide (0.04 g, 0.15 mmol) were 
dissolved in a solvent mixture of anhydrous methanol (10 
mL) and anhydrous dichloromethane (5 mL) in a Schlenk 
flask. The mixture was stirred at room temperature for 24 
hours in the dark. The mixture was filtered over Celite and 
the solvent removed from the filtrate in vacuo to give a 
white solid. Yield: 0.018 g (14 %). 1H NMR (300 MHz, d4-MeOD): δ 7.63 (broad s, 1H, NCH), 7.48-7.00 (m, 15H, aro-
matic), 6.86 (broad s, 1H, NCH), 4.12 (t, 2H, CH2), 3.81(t, 
2H, CH2). 13C{1H} NMR (75 MHz, d4-MeOD): δ 144.0 (C), 
131.4 (CH), 129.4 (CH), 129.2 (CH), 124.5 (CH), 120.8 
(CH), 78.6 (C), 62.4 (CH2), 56.3 (CH2). HRMS (ESI+): Calcd 
for C48H44AgN4O2 [2M-AgCl2]+: 817.2512. Found: 
817.2529. Anal. Calcd for C144H132Ag5Cl5N12O6 i.e. 4:1 
Ag(NHC)Cl:[Ag(NHC)2]Cl: C, 60.83; H, 4.68; N, 5.91. Found: 
C, 60.80; H, 4.50; N, 5.80.  
Synthesis of silver complex 6a. Imidazolium salt 1a 
(0.40 g, 0.84 mmol) and silver oxide (0.19 g, 0.84 mmol) 
were dissolved in dichloromethane (40 mL) and heated at 
reflux for 24 hours in the dark. The solution was filtered 
over Celite, and the solid washed with dichloromethane. 
The solvent was removed from the filtrate in vacuo to give 
the product as a white crystalline solid. Yield: 0.21 g (43 
%). 1H NMR (300 MHz, CDCl3): δ 7.34 – 6.95 (m, 16H, aro-
matic), 3.88 (s, 3H, CH3). 13C{1H} NMR (75 MHz, d6-DMSO): δ 139.8 (C), 134.8 (C), 132.2 (C), 131.0 (CH), 130.2 (CH), 
128.2 (CH), 128.1 (CH), 127.8 (CH), 123.2 (CH), 121.1 
(CH), 118.5 (CH), 76.8 (CH), 40.1 (CH3). HRMS (ESI+): 
Calcd for C46H38AgCl2N4 [2M-AgI2]+: 825.1516. Found: 
825.1532. Anal. Calcd for C23H19AgClIN2.3/2CH2Cl2: C, 
40.81; H, 3.08; N, 3.89. Found: C, 40.90; H, 3.20; N, 4.10. 
Synthesis of silver complex 6c. Imidazolium salt 1c 
(0.15 g, 0.28 mmol) and silver oxide (0.07 g, 0.28 mmol) 
were dissolved in dichloromethane (15 mL) and heated at 
reflux for 24 hours in the dark. The solution was filtered 
over Celite, and the solid washed with dichloromethane. 
The solvent was removed from the filtrate in vacuo to give 
a yellow solid which was recrystallized from dichloro-
methane/pentane to yield the product as a yellow solid. 
Yield: 0.08 g (47 %). 1H NMR (300 MHz, CDCl3): δ  7.45-
7.09 (m, 15H, aromatic & NCH), 6.96 (s, 1H, NCH), 4.15 (t, 
2H, N-CH2CH2CH2CH3), 1.80 (dt, 2H, N-CH2CH2CH2CH3), 
1.32 (m, 2H, N-CH2CH2CH2CH3), 0.94 (dd, 3H, N-
CH2CH2CH2CH3). 13C{1H} NMR (75 MHz, CDCl3): δ 141.1 
(C), 140.0 (C), 135.8 (C), 131.6 (CH), 130.7 (CH), 130.6 
(CH), 128.5 (CH), 128.2 (CH), 128.1 (CH), 123.6 (CH), 
118.2 (CH), 77.8 (C), 53.6 (CH2), 33.5 (CH2) 19.7 (CH2), 
13.8 (CH3). HRMS (ESI+): Calcd for C52H50AgCl2N4 [2M-
AgI2]+: 909.2460. Found: 909.2609. Anal. Calcd for 
C26H25AgClIN2.2/3C5H12: C, 51.52; H, 4.86; N, 4.10. Found: 
C, 51.90; H, 5.20; N, 4.00. Single crystals suitable for X-ray 
diffraction analysis were grown by the vapor diffusion of 
pentane into a concentrated solution of the product in di-
chloromethane. 
Synthesis of silver complex 6e. Imidazolium salt 1e 
(0.32 g, 0.63 mmol) and silver oxide (0.14 g, 0.63 mmol) 
were dissolved in dichloromethane (30 mL) and heated at 
reflux for 24 hours in the dark. The solution was filtered 
over Celite, and the solid washed with dichloromethane. 
The solvent was removed from the filtrate in vacuo to yield 
the product as a white solid. Yield: 0.12 g (31 %). 1H NMR 
(300 MHz, d4-MeOD): δ 7.00-6.55 (m, 16H, aromatic & 
NCH), 3.83 (m, 2H, N-CH2CH2OH), 3.45 (m, 2H, N-
CH2CH2OH). 13C{1H} NMR (75 MHz, CDCl3): δ 140.9 (C), 
140.2 (C), 135.8 (C), 132.5 (CH), 131.5 (CH), 130.7 (CH), 
130.4 (CH), 128.4 (CH), 128.1 (CH), 127.8 (CH), 123.2 (CH) 
120.1 (CH), 77.3 (C), 62.6 (CH2), 55.6 (CH2). 
C48H42AgCl2N4O2 [2M-I]+: 887.1883. Found: 887.1864. 
Anal. Calcd for C48H42AgCl2IN4O2.1/2CH2Cl2: C, 55.22; H, 
4.11; N, 5.31. Found: C, 55.20; H, 3.80; N, 5.00. 
Cytotoxicity studies. Cells were incubated in 96-well 
plates, at 2 x 103 cells per well in 200 µL of growth media 
(RPMI 1640 supplemented with 10 % foetal calf serum, 
sodium pyruvate (1mM) and L-glutamine (2 mM). Cells 
were incubated for 24 hours at 37 °C in an atmosphere of 
5 % CO2 prior to drug exposure. Silver compounds and cis-
platin were dissolved in dimethylsulfoxide at a concentra-
tion of 25 mM and diluted with medium to obtain drug so-
lutions ranging from 50 to 0.049 µM. The final dimethyl-
sulfoxide concentration was 0.1 % (v/v) which is non-
toxic to cells. Drug solutions were applied to cells and in-
cubated for 96 hours at 37 °C in an atmosphere of 5 % CO2. 
The solutions were removed from the wells and fresh me-
dium added to each well along with 20 µL MTT (5mg mL-
1), and incubated for 4 hours at 37 °C in an atmosphere of 
5 % CO2. The solutions were removed and 150 µL dime-
thylsulfoxide was added to each well to dissolve the pur-
ple formazan crystals. A plate reader was used to measure 
the absorbance at 540 nm. Lanes containing medium only, 
and cells in medium only (no drug), were used as blanks 




respectively. Cell survival was determined as the absorb-
ance of treated cells divided by the absorbance of controls 
and expressed as a percentage. The concentration re-
quired to kill 50 % of cells (IC50) was determined from 
plots of % survival against drug concentration. The results 
were expressed as the mean  standard deviation for 
three independent experiments. All compounds and cis-
platin were initially tested against Panc 10.05 (pancreatic 
cancer) and ARPE-19 (non-cancer retinal epithethial cell 
line). The selectivity index (SI) was determined (defined 
as the mean IC50 for ARPE-19 cells divided by the mean 
IC50 for Panc10.05 cells). Any compound with an SI value 
greater than cisplatin was selected for further evaluation 
against two other cancer cell lines (MiaPaCa-2 and BE). A 
selection of compounds with lower SI values than cisplatin 
were also tested in order to determine whether or not SI 
values against MiaPaCa-2 and BE cell lines remained low 
or whether cell dependent variations were observed. Sta-
tistical analysis was conducted using a t-test with signifi-
cance defined as a p value <0.05 or p<0.01.  
Hydrophobicity measurements. Equal volumes of oc-
tanol and NaCl-saturated water were stirred at room tem-
perature for 24 hours and separated to give octanol-satu-
rated water and water-saturated octanol. Accurate 
amounts of the complexes were dissolved in the water-
saturated octanol (25 mL). 3 mL of octanol-saturated wa-
ter was placed in a centrifuge tube and 3 mL of water-sat-
urated octanol containing the complex was layered on top. 
The samples were shaken for 4 hours using a vibrax ma-
chine at 500 gmin-1. The layers were separated and the 
water-saturated octanol layer was retained for analysis 
using UV/vis spectroscopy. Using the maximum absorb-
ance for each complex, the average of six runs was calcu-
lated, and rearrangement of individual calibration graphs 
gave the final [C]org. The [C]org and [C]aq were used to de-
termine the partition coefficient log P. 
Biomembrane sensing device. Full details of the device, 
apparatus used  and operation is fully  described in a pre-
vious reference.56 The microfabricated Pt/Hg electrode 
coated with DOPC (Avanti Polar Lipids Alabaster, AL, US, 
>99% purity) was contained in a sealed flow cell.  In the 
RCV experiments the fabricated rectangular platinum 
electrode on the wafer was employed as a counter elec-
trode and a Ag/AgCl/3.5 M KCl reference electrode was in-
serted into the flow cell. All potentials in this paper are 
quoted versus this reference electrode. A constant flow of 
0.1 M KCl, calcined at 600 °C for 2 h and buffered at pH 7.4 
with 0.01 M phosphate (hereinafter referred to as phos-
phate buffered saline or PBS) was passed over the Pt/Hg 
electrode using a peristaltic pump. The electrodes were 
connected to a potentiostat (PGSTAT 30 Autolab potenti-
ostat Ecochemie, Utrecht, Netherlands) interfaced to a 
Powerlab signal generator (AD Instruments Ltd) and con-
trolled by Scope(c) software.  Rapid cyclic voltammetry 
(RCV) scans were obtained by applying a saw-tooth wave-
form from -0.4 to -1.2 V with ramp rate 40 Vs-1 applied to 
the electrode surface. In the absence of faradaic reactions, 
the current on the RCV plot is directly proportional to the 
capacitance of the surface and is displayed as a function of 
voltage. In response to the applied voltage ramp, the DOPC 
monolayers undergo two pronounced phase transitions 
characterized by two capacitance current peaks. These 
peaks correspond to structural changes of, and the 
redistribution of charges and polar groups on the mono-
layer interface. All assays were carried out in pH 7.4 PBS 
with continuous scanning from -0.4 to -1.2 V. The com-
pounds are tested for 400 seconds after which PBS is 
flushed through for 400 seconds to allow for any recovery 
of the DOPC layer initial structure to take place. Both com-
pound interaction and DOPC layer depuration take place 
with the monolayer undergoing two disruptive reversible 
phase transitions where each molecule of lipid is in con-
tact with the aqueous phase. Increasing the concentration 
of the compounds in test media gives rise to increased re-
sponses following compound interaction with the DOPC 
layer. This is shown as enhanced peak suppression. The 
effect of compound dose on the RCV plot emphasizes the 
effect of compound type on the nature of and sensitivity to 
their interaction with the DOPC coated electrode. The de-
gree of RCV scan recovery is related to the degree of DOPC 
structure restoration which in turn is related to the degree 
of reversibility of the interaction.  
The LoD is measured by plotting a calibration graph of ca-
pacitance current peak height vs. compound solution con-
centration following interaction with the respective com-
pound. Subsequently the reproducibility of the capaci-
tance current peak height from the RCVs of the DOPC 
coated Hg electrode in PBS was estimated by taking ten 
replicate measurements. The three times standard devia-
tion (SD) of this capacitance peak height was calculated as 
a control. Accordingly the concentration of test compound 
which has an equivalent suppressive effect on the capaci-
tance current peak height relating to three times the SD of 
the control was read off the calibration curve to estimate 
the detection limit values. The detection limits are esti-
mated and quoted as the minimum concentration of com-
pound in water to elicit a response and these detection 
limits are related to compound molecular structure and 
the known biological effect of each compound. The LoD is 
inversely proportional to the ability of the compound to 
disrupt the layer structure and organization. 
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